Summary
AbbVie Inc. (ABBV) filed an 8-K on July 29, 2016, to report its financial results for the second quarter ended June 30, 2016. This filing primarily incorporates by reference the press release announcing these results, providing investors with key financial performance indicators for the period. Investors should refer to the furnished press release (Exhibit 99.1) for detailed information on AbbVie's operational performance, revenue generation, profitability, and any forward-looking statements made by the company during that time. The main purpose of this 8-K is to formally disclose the company's quarterly earnings. The Chief Financial Officer, William J. Chase, signed the report, underscoring the official nature of the financial information being disseminated. While the 8-K itself is brief, it serves as the official SEC record linking to the comprehensive press release that contains the substantive financial and operational details investors would analyze.
Key Highlights
- 1AbbVie Inc. filed an 8-K on July 29, 2016, reporting Q2 2016 financial results.
- 2The filing primarily incorporates a press release announcing the second quarter results.
- 3The press release (Exhibit 99.1) contains detailed operational and financial performance information for the quarter ended June 30, 2016.
- 4Item 2.02 of the 8-K addresses Results of Operations and Financial Condition.
- 5Item 9.01 lists the incorporated press release as Exhibit 99.1.
- 6The report was signed by William J. Chase, Executive Vice President and Chief Financial Officer.